The clinical and neurobehavioral course of Down syndrome and dementia with or without new-onset epilepsy

Discussion New-onset epilepsy seems to occur early in the course of dementia in DS patients. Patients generally respond to treatment. A great burden of neuropsychiatric symptoms is seen. Future studies need to explore the relationship between β-amyloid accumulation and epileptiform activity and attend to the care and needs of DS patients with dementia and seizures.
Source: Epilepsy and Behavior - Category: Neurology Source Type: research

Related Links:

Publication date: Available online 11 November 2019Source: SeizureAuthor(s): Colin Reilly, Tove Hallböök, Gerd Viggedal, Bertil Rydenhag, Paul Uvebrant, Ingrid OlssonAbstractPurposeThe aim of this study was to compare parent-reported Health Related Quality of Life (HRQoL) and behaviour of young people before (baseline) and two years after paediatric epilepsy surgery (follow-up).MethodsThe parents of 107 children who underwent epilepsy surgery completed surveys focussing on different aspects of child HRQoL and behaviour at baseline and follow-up. Parents of children with multiple disabilities (n = 27...
Source: Seizure - Category: Neurology Source Type: research
Publication date: January 2020Source: Epilepsy &Behavior, Volume 102Author(s): Elena Fonseca, Lorena Guzmán, Manuel Quintana, Laura Abraira, Estevo Santamarina, Xavier Salas-Puig, Manuel ToledoAbstractObjectiveThe aim of this study was to evaluate the efficacy, tolerability, and retention of brivaracetam (BRV) in genetic generalized epilepsy (GGE) in real-life practice.MethodsThis is a retrospective cohort study of adult patients with GGE in whom BRV was started between 2016 and 2018, completing a follow-up period of ≥ 6 months. Clinical and electroencephalogram (EEG) characteristics were analyzed at b...
Source: Epilepsy and Behavior - Category: Neurology Source Type: research
Publication date: January 2020Source: Epilepsy &Behavior, Volume 102Author(s): Renandro de Carvalho Reis, Kelson James Almeida, Luciano da Silva Lopes, Cíntia Maria de Melo Mendes, Edson Bor-Seng-ShuAbstractThis paper aimed to systematically examine the efficacy and adverse event (AE) profile of cannabidiol and medicinal cannabis by analyzing qualitative and meta-analytic data. We used the terms (“Cannabidiol” OR “Cannabis”) AND “Epilepsy” AND (“Treatment” OR “Therapeutics”) as keywords to retrieve studies indexed on PubMed, ScienceDirect, and CENTRAL d...
Source: Epilepsy and Behavior - Category: Neurology Source Type: research
In conclusion, BR echogenic signal alterations in TCS can be a biomarker for depression in epilepsy, but it might not be associated with epilepsy itself. The alterations of SN echogenic area and TV width in TCS may reflect a potential role of SN and diencephalon structure in the pathogenesis of epilepsy, which needs to be further elucidated.
Source: Epilepsy and Behavior - Category: Neurology Source Type: research
ConclusionPatients affected by late-onset epilepsy with unknown etiology showed a significant decline of cognition at follow-up, independently from number and efficacy of AEDs received. These results deserve verification in larger longitudinal cohorts.
Source: Epilepsy and Behavior - Category: Neurology Source Type: research
In the Editorial titled “Prevalence and Severity of Alzheimer Disease in Individuals With Down Syndrome,” published online November 19, 2018, a typographical error was corrected in the sentence in the third paragraph that includes the phrase “late-onset epilepsy increased mortality risk in individuals with DS and dem entia by 10-fold.” The phrase “in individuals with DS and dementia” was changed to “in individuals with DS without dementia.”
Source: JAMA Neurology - Category: Neurology Source Type: research
Purpose of review: Alzheimer's disease is most likely universal in older individuals with Down syndrome, due to having three copies of the amyloid precursor protein gene, resulting in amyloid-beta plaque deposition. Down syndrome is an important population in which to consider clinical trials of treatments to prevent or delay the development of dementia. However, assessment of subtler cognitive changes is challenging due to the presence of intellectual disability. Recent findings: Recent research confirmed that older adults with Down syndrome often present with cognitive decline: more than 80% may experience dementia by a...
Source: Current Opinion in Psychiatry - Category: Psychiatry Tags: NEURODEVELOPMENTAL DISORDERS: Edited by James C. Harris Source Type: research
DISCUSSION: New-onset epilepsy seems to occur early in the course of dementia in DS patients. Patients generally respond to treatment. A great burden of neuropsychiatric symptoms is seen. Future studies need to explore the relationship between β-amyloid accumulation and epileptiform activity and attend to the care and needs of DS patients with dementia and seizures. PMID: 28109983 [PubMed - as supplied by publisher]
Source: Epilepsy and Behaviour - Category: Neurology Authors: Tags: Epilepsy Behav Source Type: research
Abstract PURPOSE OF REVIEW: Alzheimer's disease is most likely universal in older individuals with Down syndrome, due to having three copies of the amyloid precursor protein gene, resulting in amyloid-beta plaque deposition. Down syndrome is an important population in which to consider clinical trials of treatments to prevent or delay the development of dementia. However, assessment of subtler cognitive changes is challenging due to the presence of intellectual disability. RECENT FINDINGS: Recent research confirmed that older adults with Down syndrome often present with cognitive decline: more than 80% may ex...
Source: Epilepsy Curr - Category: Neurology Authors: Tags: Curr Opin Psychiatry Source Type: research
CONCLUSIONS: New onset epilepsy seems to occur early in the course of dementia in DS patients. It is unclear if epilepsy has a role in dementia progression. Treatment response was generally good except for epileptic myoclonus. Future studies are needed to study patients with DS and dementia, with and without epilepsy and investigate the interplay between Alzheimer’s dementia pathology.Disclosure: Dr. Gholipour has nothing to disclose. Dr. Sarkis has nothing to disclose. Dr. El-Chemali has nothing to disclose.
Source: Neurology - Category: Neurology Authors: Tags: Epilepsy/Clinical Neurophysiology (EEG): Clinical Epilepsy Source Type: research
More News: Alzheimer's | Dementia | Down's Syndrome | Epilepsy | Neurology | Psychiatry | Study